Oncology Biologics: Paradigm Shift in Cancer Treatment

Biological therapies including monoclonal antibodies, immunotherapy, biotherapy, or biological response modifier therapy treatments have revolutionized the treatment of cancers in recent years. Many types of cancers are now considered a chronic disease that can be managed through a combination of new generation of biologics, radiation and small molecule oncology drugs.

Oncology Biologics: Paradigm Shift in Cancer Treatment will discuss the innovations in oncology and next generation of cancer biologics and how these innovations are helping thousands of cancer patients worldwide. This innovative event will focus on current innovations in oncology biologics as well as future drug development and novel treatment options.

This conference will discuss the advancement in a board variety of oncology biologics including: Immunotherapy and cancer vaccines Antibody-drug conjugates (mix of antibody + toxin – targeted delivery) to target tumors Immunoconjugates Anti-angiogenesis biologics Stem cell targeting biologics Novel biologics beyond antibodies Bispecific antibodies Oncology biologics enabling diagnostics technologies Personalized cancer treatment This is the most exciting time for oncology biologics. Some of the recent immune activating antibodies have demonstrated unprecedented life-saving benefits in melanoma and other immunocompromised cancers. The recent approval of Her-2 targeting ADC such Kadcyla has rejuvenated the moribund field of ADC.